John Rim, Samsung Biologics CEO
July 13, 2022 02:12 PM EDT
Pharma
Manufacturing

Amid glob­al ex­pan­sion, Sam­sung Bi­o­log­ics pledges emis­sions drops in new ESG re­port

Tyler Patchen

News Reporter

As the biotech man­u­fac­tur­ing arm of one of Ko­rea’s largest con­glom­er­ates is aim­ing to rapid­ly ex­pand its glob­al pres­ence af­ter a large in­vest­ment by its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times